Compare Enveric Biosciences Inc (ENVB) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Phillips 66 — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Phillips 66 trades at $281 (market cap $108.38B). The key difference: Phillips 66 is far larger — about 16200.3× Enveric Biosciences Inc's market cap, and Phillips 66 pays a 1.87% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Phillips 66 for 62 Days on average.
| ENVB | PSX | |
|---|---|---|
Market Cap | $6.69M | $108.38B |
Volume | 41,141 | 1,841,742 |
Sector | Health | Energy |
52-Week High | $10.80 | $281.60 |
52-Week Low | $1.27 | $126.76 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | -$1.60M | $124.85B |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
PSX trades at $281.60, up 4.38% today, near its 52-week high. The stock shows bullish technical momentum with strong moving average support. Fundamentally, the company has beaten earnings estimates for three consecutive quarters, with a P/E of 15.5 and robust ROE of 24.02%. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
Outlook remains positive with analyst consensus at Buy (57% of ratings) and a $279 price target. Key opportunities include sustained refining profitability and debt reduction. Risks involve volatile energy markets and potential policy impacts on diesel exports. Cash flow is projected to rebound to $3.0B in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
